GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » Buyback Yield %

Genetic Signatures (ASX:GSS) Buyback Yield % : -5.49 (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Genetic Signatures's current buyback yield was -5.49%.


Genetic Signatures Buyback Yield % Historical Data

The historical data trend for Genetic Signatures's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures Buyback Yield % Chart

Genetic Signatures Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only -0.18 -12.06 -0.10 -0.16 -0.01

Genetic Signatures Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.18 -0.02 - -18.44

Competitive Comparison of Genetic Signatures's Buyback Yield %

For the Diagnostics & Research subindustry, Genetic Signatures's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Signatures's Buyback Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Genetic Signatures's Buyback Yield % falls into.



Genetic Signatures Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Genetic Signatures's Buyback Yield for the fiscal year that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.001 + 0.011) / 75.288123582
=-0.01%

Genetic Signatures's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-0.48 + 7.959) * 2 / 81.120105
=-18.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2023) data.


Genetic Signatures Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Signatures (ASX:GSS) Business Description

Traded in Other Exchanges
N/A
Address
7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.